ArticleVeterinary sciences2026
A Lipid Nanoparticle-Formulated GP5-mRNA Vaccine Induces PRRSV-Specific Humoral and Cellular Immune Responses in BALB/c Mice.
Article in Veterinary sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Porcine reproductive and respiratory syndrome virus (PRRSV) remains a major threat to the global swine industry, and the continuous emergence of genetically diverse strains poses challenges to vaccine development. In this study, a lipid nanoparticle-formulated mRNA vaccine encoding the PRRSV GP5 protein was constructed, and its preliminary immunogenicity was evaluated in BALB/c mice. The full-length ORF5 gene was amplified and cloned into the pIVT5 vector to generate the recombinant plasmid pIVT5-GP5. GP5-mRNA was synthesized via in vitro transcription and transfected into Marc-145 cells to verify antigen expression. Indirect immunofluorescence assay showed specific fluorescence signals in GP5-mRNA-transfected cells, and Western blotting further confirmed the expression of GP5 protein. The GP5-mRNA was subsequently encapsulated into lipid nanoparticles to prepare the GP5 mRNA-LNP vaccine formulation. BALB/c mice were immunized intramuscularly to evaluate humoral and cellular immune responses. The GP5 mRNA-LNP vaccine induced a GP5-specific IgG response, and sera collected on days 28, 35, and 42 after the initial immunization showed detectable neutralizing activity against PRRSV. Flow cytometric analysis showed an increased proportion of CD3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.